StockNews.com upgraded shares of Summit Therapeutics (NASDAQ:SMMT – Get Rating) from a sell rating to a hold rating in a research note released on Monday morning.
Summit Therapeutics Stock Performance
SMMT stock opened at $1.53 on Monday. The company has a debt-to-equity ratio of 3.90, a current ratio of 16.93 and a quick ratio of 16.93. The company’s 50-day moving average is $3.05 and its 200-day moving average is $2.17. Summit Therapeutics has a 1 year low of $0.66 and a 1 year high of $5.78.
Insider Buying and Selling at Summit Therapeutics
In other news, CFO Ankur Dhingra bought 196,362 shares of the stock in a transaction dated Tuesday, March 7th. The shares were bought at an average cost of $1.05 per share, with a total value of $206,180.10. Following the completion of the transaction, the chief financial officer now directly owns 234,558 shares of the company’s stock, valued at $246,285.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Mahkam Zanganeh purchased 15,973,743 shares of the business’s stock in a transaction on Wednesday, March 8th. The stock was acquired at an average price of $1.05 per share, for a total transaction of $16,772,430.15. Following the purchase, the chief executive officer now owns 23,395,269 shares of the company’s stock, valued at $24,565,032.45. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Ankur Dhingra acquired 196,362 shares of the stock in a transaction dated Tuesday, March 7th. The stock was bought at an average cost of $1.05 per share, with a total value of $206,180.10. Following the completion of the purchase, the chief financial officer now owns 234,558 shares of the company’s stock, valued at $246,285.90. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 392,659,985 shares of company stock valued at $412,292,984. Company insiders own 87.50% of the company’s stock.
Institutional Investors Weigh In On Summit Therapeutics
About Summit Therapeutics
Summit Therapeutics Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
- Get a free copy of the StockNews.com research report on Summit Therapeutics (SMMT)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.